profit from every $100 of sales.
$0$100
10x Genomics
$58.19-1.54% today
+255.9% in 1 year
1-year low $15.461-year high $97.74
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What 10x Genomics sold, what it kept, and what it did with the cash.
Sales went from $516 million in 2022 to $643 million in 2025, with -$43.5 million of profit last year.
SalesProfit
10x Genomics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| 10x Genomics | No profit yet | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads 10x Genomics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 299 | 490 | 516 | 619 | 611 | 643 | |
| 240 | 416 | 396 | 409 | 414 | 444 | |
| – | – | -168 | -204 | -195 | -111 | |
| -515 | -27 | -128 | -205 | -134 | 4 | |
| -543 | -58 | -166 | -255 | -183 | -44 | |
| -5.37 | -0.53 | -1.46 | -2.18 | -1.52 | -0.35 | |
| 80.4% | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% | |
| – | – | -32.5% | -33.0% | -31.9% | -17.2% | |
| -181.6% | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 929 | 1,019 | 1,029 | 965 | 919 | 1,041 |
| Cash | 664 | 587 | 220 | 359 | 344 | 474 |
| Total debt | – | – | 95 | 95 | 83 | 84 |
| Total liabilities | 190 | 201 | 223 | 224 | 209 | 245 |
| 739 | 818 | 806 | 741 | 710 | 796 | |
| 101 | 110 | 114 | 117 | 120 | 125 | |
| -57.0% | -5.1% | -14.2% | -23.5% | -17.7% | -3.6% | |
| -73.4% | -7.1% | -20.6% | -34.4% | -25.7% | -5.5% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -218 | -21 | -34 | -15 | 7 | 136 | |
| 37 | 101 | 132 | 50 | 13 | 6 | |
| -255 | -123 | -165 | -65 | -7 | 130 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 49 | 96 | 137 | 167 | 141 | 109 |
Valuation
- –
- –
- –
- 9.8×
- 11.9×
- 58.8×
- 1,858.4×
- 1.7%
- -0.6%
- 0.0%
Profitability
- 69.1%
- -17.2%
- -6.8%
- -0.9%
- -3.7%
- -15.1%
- -2.9%
- -2.2%
- -4.3%
- 36.2%
Growth
- +16.6%
- –
- +2,371.2%
- –
- +3.1%
Financial health
- -99.7×
- 0.11
- 8.0%
- -6,450.5×
- 4.46
- 5.42
- 0.63
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 28%of 952
Bottom 13%of 884
Top 33%of 886
Top 46%of 987
What analysts expect
- Average price target
- $22.14
- Range
- $17.00 – $30.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.10 | -0.29 | +65.5% |
| Feb 12, 2026 | -0.13 | -0.19 | +31.6% |
| Nov 6, 2025 | -0.22 | -0.07 | −214.3% |
| Aug 7, 2025 | 0.28 | -0.35 | +180.0% |
| May 8, 2025 | -0.36 | -0.45 | +20.0% |
| Feb 12, 2025 | -0.40 | -0.29 | −37.9% |
| Oct 29, 2024 | -0.30 | -0.34 | +11.8% |
| Aug 8, 2024 | -0.32 | -0.47 | +31.9% |
News
Global Clinical Genomics Software Market Report 2026 | Capitalize on 14.8% CAGR Through 2030 as Google, Microsoft, NVIDIA and Illumina Scale AI, Cloud and Precision MedicineYahoo Finance · Nov 9, 2026Global Clinical Knowledge Graphs for Genomics Market Report 2026 | Capitalize on 20.7% CAGR as Microsoft, IBM, Illumina and Genomenon Scale AI, Cloud and Precision MedicineYahoo Finance · Oct 30, 2026Cathie Wood-Led Ark Invest's Biggest Q3 Winners and Losers — PLTR, NVDA, TXG Led While TSLA, RKLB DraggedYahoo Finance · Oct 17, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
39No pass
Philip Fisher
38No pass
Peter Lynch
56No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
31No pass
Questions about 10x Genomics
Is 10x Genomics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the 10x Genomics AI analysis
What does 10x Genomics do?
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. It is in Medical Devices, based in Pleasanton, CA, United States, with 1,178 employees.
Does 10x Genomics pay a dividend?
No. 10x Genomics does not pay a dividend at the moment.
Is 10x Genomics stock halal?
Yes. 10x Genomics passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has 10x Genomics stock done over the past year?
Up 255.9% over the past twelve months, to $58.19. It traded between $15.46 and $97.74 and is 40.5% below its high.
Who are 10x Genomics's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with 10x Genomics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.